Echocardiography in Confirmed and Highly Suspected Symptomatic COVID-19 Patients and Its Impact on Treatment Change

Table 3

Biological characteristics of the patients included.

Characteristics	All TTE/TEE patients (n = 56)	According to treatment change		value
		TTE/TEE patients with treatment change induced by the TTE N = 9 (16%)	TTE/TEE patients without treatment change induced by the TTE N = 47 (84%)
Creatinine, median (IQR), µmol/l	80 (58.5–124)	90 (77–126)	74 (58–122)	0.4961
Hs Troponin T, median (IQR), pg/ml	21 (11.8–57)	101.5 (30.3–111.2)	20.3 (11.6–43.5)	0.0506
NT-pro BNP, median (IQR), pg/ml	628 (177–2530)	750 (339–4038)	552.5 (155.5–2138.5)	0.3197
D-dimer, median (IQR), ng/ml	2970 (1130–11620)	20000 (2690–20000)	2770 (1350–9330)	0.0142
Fibrinogen, median (IQR), g/l	7.84 (5.72–10.2)	7.15 (5.17–7.95)	8.64 (5.89–10.2)	0.4111
Blood type, N (%)	O+: 17 (46.0); A+: 9 (24.3); A−: 2 (5.4); AB+: 2 (5.4); B+: 7 (18.9)	O+: 4 (57.1); A+: 0; A−: 1 (14.3); AB+: 1 (14.3); B+: 1 (14.3)	O+: 13 (43.4); A+: 9 (30.0); A−: 1 (3.3); AB+: 1 (3.3); B+: 6 (20.0)	0.2900

NT-pro BNP : N-terminal pro B natriuretic peptide; Hs Troponin T: high-sensitivity cardiac Troponin T.